ADAR1 Capital Management »

Engene Therapeutics shares owned by ADAR1 Capital Management

Quarter-by-quarter ownership of Engene Therapeutics (ENGN) shares owned by ADAR1 Capital Management from 13F filings

Historical chart of ADAR1 Capital Management investment in Engene Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Engene Therapeutics held by ADAR1 Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Engene Therapeutics by ADAR1 Capital Management

Quarter filed Position value Share count Share price at filing
2026-06-30 $3.6M 2.1M 1.73

More positions owned by ADAR1 Capital Management

Abivax Sa Sponsored Ads (ABVX)
Protagonist Therapeutics (PTGX)
State Str Spdr S&p 500 Etf T Tr Unit Put Option (SPY)
Roivant Sciences SHS (ROIV)
Immunovant (IMVT)
Zai Lab Adr (ZLAB)
Agios Pharmaceuticals (AGIO)
Crinetics Pharmaceuticals In (CRNX)
Ea Series Trust Alpha Arch 1-3 (BOXX)
Cytokinetics Com New (CYTK)
Septerna (SEPN)
Anteris Technologies Global (AVR)
Editas Medicine (EDIT)
Denali Therapeutics (DNLI)
Spyre Therapeutics Com New (SYRE)

View all positions for ADAR1 Capital Management

Top funds holding Engene Therapeutics

Perceptive Advisors
Nextech Invest
ADAR1 Capital Management
Balyasny Asset Management
Millennium Management
Renaissance Technologies
Citadel Advisors
Affinity Asset Advisors
Jane Street
Rangeley Capital
Barclays
Elmind Capital
Two Sigma Investments
Marquette Asset Management
Jain Global

View all funds holding Engene Therapeutics